Skip to main
PSTV

PSTV Stock Forecast & Price Target

PSTV Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Plus Therapeutics Inc. is demonstrating significant progress in its drug development pipeline with key milestones expected in 2025 and 2026, particularly for its rhenium (186Re) obisbemeda treatment for CNS cancers. The company has recently secured an $18 million grant from the Cancer Prevention and Research Institute of Texas to advance its research on leptomeningeal metastases and has expanded the operational footprint of its CNSide Diagnostics platform to encompass 48 of 50 U.S. states, thus enhancing its revenue potential. The ongoing national payor coverage expansions and operational improvements within CNSide Diagnostics are likely to support enhanced adoption and increased test volumes, contributing to a positive long-term outlook for the company.

Bears say

Plus Therapeutics Inc. faces significant risks affecting its stock outlook, primarily due to the potential failure of its product candidates to demonstrate safety and efficacy in clinical trials. Additionally, the company's reliance on regulatory approval for commercial sale and suitable reimbursement presents further uncertainties that could impair financial performance. The competitive landscape and shifting macroeconomic factors further exacerbate these risks, contributing to a negative sentiment regarding the company's prospects.

PSTV has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Plus Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Plus Therapeutics Inc (PSTV) Forecast

Analysts have given PSTV a Strong Buy based on their latest research and market trends.

According to 4 analysts, PSTV has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Plus Therapeutics Inc (PSTV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.